PATENT CLAIM ANALYSIS

Application Number: 15772861
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["546", "118000"]

Abstract:
There are provided compounds of formula (I), wherein X, Ak, s, L, Q, R 1  and R 2  have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of the JAK family) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Claim (Index 1):
A compound of formula I, wherein:\n X represents halo; \n Ak represents C 1-6  alkyl optionally substituted by one or more fluorine atoms; \n s represents 1 or 2; \n L represents C(O), S(O) 2 , CH 2  or a bond; \n Q represents a 6-membered heteroaromatic ring containing 1, 2 or 3 N atoms; \n R 1  represents R 3 ; \n R 2  represents H, methyl or R 3 ; \n or R 1  and R 2 , together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated or partially unsaturated, which heterocyclic group contains one N atom (the atom to which R 1  and R 2  are attached) and wherein \n (a) the heterocyclic group contains one further heteroatom that is S and is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, C 1-4  alkyl, C 1-4  alkoxy and C 1-4  hydroxyalkyl or \n (b) the heterocyclic group optionally contains one or more further heteroatoms selected from N, O and S, is substituted by one or more substituents selected from C 1-4  hydroxyalkyl, C 1-4  carboxyalkyl and \u2014(C 1-4  alkylene)-NR a R b , and is optionally further substituted by one or more substituents selected from halo, hydroxy, oxo, CO 2 H, C 1-4  alkyl and C 1-4  alkoxy or \n (c) the heterocyclic group is fused to a fully saturated or partially unsaturated 5- or 6-membered heterocyclic ring, which heterocylic ring contains one or more heteroatoms selected from from N, O and S and is optionally substituted with one or more substituents selected from oxo and C 1-4  alkyl; \n R 3  represents\n Het x  or \n C 1-6  alkyl substituted by\n CO 2 H, \n \u2014(OCH 2 CH 2 ) 0-4 OR c , \n Het y , \n Het z , \n NR d C(O)R e  or \n S(O) 1-2 R f , \n \n \n which C 1-6  alkyl group is optionally further substituted by one or more substituents selected from halo, hydroxy and oxo; \n R a , R b , R c , R d  and R e  independently represent H or C 1-4  alkyl, \n or R a  and R b , together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated, partially unsaturated or fully aromatic and which heterocyclic group contains one N atom (the atom to which R a  and R b  are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, C 1-4  alkyl, C 1-4  alkoxy and C 1-4  hydroxyalkyl; \n R f  represents C 1-6  alkyl or C 3-7  cycloalkyl; \n Het x  represents, independently upon each occurrence, a 4- to 7-membered heterocyclic group that is fully saturated, partially unsaturated or fully aromatic, which group contains one or more heteroatoms selected from N, O and S, and which group is optionally substituted by one or more substituents selected from C 1-4  alkyl, halo, hydroxy and oxo; \n Het y  represents, independently upon each occurrence, a 5- to 10-membered heterocyclic group that is fully aromatic, which group contains one or more heteroatoms selected from N, O and S, and which group is optionally substituted by one or more substituents selected from C 1-4  alkyl, halo, hydroxy and oxo; and \n Het z  represents, independently upon each occurrence, a 4- to 7-membered heterocyclic group that is fully saturated or partially unsaturated, which group contains one or more heteroatoms selected from N, O and S, and which group is substituted by oxo or hydroxy, and which group is optionally further substituted by one or more substituents selected from C 1-4  alkyl, halo, hydroxy and oxo, \n or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 93.0
- Lexical Diversity: 1.64706
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13542153', '14041387', '15772887', '13509442', '12468188']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8483354307521387
- 35 USC 102 Novelty (BERT): 0.5830483189964201
- Combined Prediction Score: 0.8218067195765668
- Mean Citation Score: 448.274146
- Max Citation Score: 513.91565
- Similarity Product: 416.4070394716621

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test